Sandoz’s distribution and collaboration agreement to bring more affordable treatments to the US

Sandoz’s distribution and collaboration agreement to bring more affordable treatments to the US

(IN BRIEF) Sandoz to commercialize six products exclusively in the US following distribution and collaboration agreement with Adalvo. The products are aimed at treating disorders that affect millions of people in the US each year, including antifungal/antibiotic, oncology, and pulmonary. The deal advances Sandoz’s ambition to be the world’s largest and most valued generics company, with the slated launches scheduled to begin in 2024. The agreement also demonstrates the company’s commitment to ensuring patient access to critical medicines in areas of greatest unmet need, and underpins its strategy of combatting the global spread of antimicrobial resistance.

(PRESS RELEASE) BASEL, 5-MAY-2023 — /EuropaWire/ —Sandoz, a global leader in generic pharmaceuticals and biosimilars, announced that it has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.

“Sandoz is putting patients first by securing the rights to bring more affordable, equally effective treatments for a range of disorders that collectively affect millions of people in the US every year,” said Keren Haruvi, President, Sandoz Inc. “This agreement also helps advance our ambition to be the world’s largest and most valued generics company.”

These products, which are slated for near- to mid-term launches beginning in 2024, have a total addressable market size of approximately USD 3 bn, further advancing the Sandoz product pipeline in the key US generics market. The agreement also demonstrates the unwavering Sandoz commitment to pioneering patient access to critical medicines in areas of greatest unmet need.

In addition to building out the Sandoz US offering in these key areas, the antibiotic products would also underpin the Sandoz strategy of combatting the global spread of antimicrobial resistance (AMR) by driving responsible access to a broad range of appropriate treatments.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

Media Contact:

Sandoz Global Communications

Central
North America
Chris Lewis
+49 174 244 9501
chris.lewis@sandoz.com

Vicki Crafton
+1 201.213.6338 (mobile)
vicki.crafton@sandoz.com

Novartis Media Relations
E-mail: media.relations@novartis.com

Central
Richard Jarvis

North America
Julie Masow
+41 79 584 2326 +1 862 579 8456

Switzerland
Satoshi Sugimoto
+41 79 619 2035

Novartis Investor Relations
Central investor relations line:
+41 61 324 7944
E-mail: investor.relations@novartis.com

Central
North America
Samir Shah
+41 61 324 7944

Sloan Simpson
+1 862 345 4440

Nicole Zinsli-Somm
+41 61 324 3809

Parag Mahanti
+1 973 876 4912

Isabella Zinck
+41 61 324 7188

SOURCE: Sandoz

EDITOR'S PICK:

EuropaWire PR Editor

Recent Posts

Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group

(IN BRIEF) Digi Communications has announced the finalization of two export credit facilities agreements totaling…

2 hours ago